David Altshuler - Vertex Pharmaceuticals Independent Director

VRTX -- USA Stock  

Earning Report: October 23, 2019  

  Director
Dr. David Altshuler, M.D., Ph.D., is Executive Vice President Global Research, Chief Scientific Officer of Vertex Pharmaceuticals Incorporated. Dr. Altshuler was our Executive Vice President, Global Research and Chief Scientific Officer since January 2015 and was a member of our Board of Directors from May 2012 through December 2014. Dr. Altshuler was one of four founding members of the Broad Institute, a research collaboration of Harvard, the Massachusetts Institute of Technology, The Whitehead Institute and the Harvard Hospitals. He served as the Director of the Institutes Program in Medical and Population Genetics from 2003 through December 2014 and as the Institutes Deputy Director and Chief Academic Officer from 2009 through December 2014. Dr. Altshuler joined the faculty at Harvard Medical School and the Massachusetts General Hospital in 2000 and held the academic rank of Professor of Genetics and Medicine from 2008 through December 2014. He served as Adjunct Professor of Biology at MIT from 2012 through December 2014. Dr. Altshuler earned a B.S. from MIT, a Ph.D. from Harvard University and an M.D. from Harvard Medical School. Dr. Altshuler completed his clinical training in Internal Medicine, and in Endocrinology, Diabetes and Metabolism, at the Massachusetts General Hospital.
Age: 53  Director Since 2015      
617 341-6100  www.vrtx.com

David Altshuler Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95 M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Donal OConnorPerrigo Company Plc
2014
Michael TrimbleOrigin Agritech Limited
2006
Michael BrownRegeneron Pharmaceuticals
1991
Paul BisaroZoetis
2015
Theodore SamuelsPerrigo Company Plc
2017
Gary KunklePerrigo Company Plc
2009
Ashok GangulyDr Reddys Laboratories Ltd
2009
William SteereZoetis
2013
Ravi BhoothalingamDr Reddys Laboratories Ltd
2000
Frank DAmelioZoetis
2016
Huda ZoghbiRegeneron Pharmaceuticals
2016
William DoyleZoetis
2015
Fei WangOrigin Agritech Limited
2019
Gregory NordenZoetis
2013
Jacqualyn FousePerrigo Company Plc
2012
Gary CohenPerrigo Company Plc
2009
Robert ScullyZoetis
2013
Geoffrey ParkerPerrigo Company Plc
2016
Geoffery MerszeiOrigin Agritech Limited
2016
Allan ObermanDr Reddys Laboratories Ltd
2019
George SingRegeneron Pharmaceuticals
1988

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased over 100 shares of
a day ago
Traded for 24.76
Purchased over 200 shares of
a day ago
Traded for 53.38
Purchased over 60 shares of
a day ago
Traded for 78.1
Also please take a look at World Market Map. Please also try Price Ceiling Movement module to calculate and plot price ceiling movement for different equity instruments.
Search macroaxis.com